Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Obacunone is a natural limonoid triterpenoid found in various citrus fruits and medicinal plants, notably Dictamnus dasycarpus and Phellodendron amurense. It is recognized for its multiple pharmacological properties, including antioxidant, anti-inflammatory, antifungal, antitumor, anti-fibrotic, and potential metabolic disease-modulating effects. Obacunone acts as a potent agonist of NRF2 (Nuclear factor erythroid 2-related factor 2), a regulator of cellular antioxidant responses, and has also been identified as a histone deacetylase 1 inhibitor with downstream suppression of p38 MAPK signaling. The compound’s mechanisms are multi-target in nature, conferring cytoprotection from oxidative stress, inhibition of inflammation, reduction of fibrosis, and potential suppression of certain tumors. Obacunone is under preclinical or early development for a range of indications, including infections (antifungal and antiviral), acute lung injury, fibrotic diseases, metabolic disorders such as hypercholesterolemia and osteoporosis, and cancer[1][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on obacunone.